“…Furthermore, the need for pump-based devices and associated equipment to maintain flow will likely limit miniaturization. In this regard, pumpless technologies with lowresistance diffusion membranes such as the Novalung interventional lung assist device (Novalung, Heilbronn, Germany) are now being explored for use in intensive care settings for removal of CO 2 in patients experiencing trauma, infection, and acute respiratory disease syndrome or even as a bridge to lung transplantation (13,15,26,46,51). However, even though these emerging approaches hold substantial potential for bridging toward transplantation, unlike the increasingly popular ventricular-assist devices that are emerging therapies for treating heart failure, transportable lung-assist devices are still in the research phase (74 -76, 188).…”